JOHN KIRKWOOD to Patient Selection
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Patient Selection.
Connection Strength
0.311
-
Developing agents for the therapeutic prevention of melanoma: can the assessment of cutaneous precursor lesions help? Future Oncol. 2020 Mar; 16(9):413-415.
Score: 0.131
-
Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010 Apr; 133(4):646-53.
Score: 0.066
-
Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol. 2009 Jun 01; 27(16):2583-5.
Score: 0.062
-
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389.
Score: 0.031
-
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007 Apr 15; 13(8):2422-8.
Score: 0.013
-
Recent advances in the care of the patient with malignant melanoma. Ann Surg. 1997 Jan; 225(1):1-14.
Score: 0.007